Cargando…
Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry?
The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cyto...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555133/ https://www.ncbi.nlm.nih.gov/pubmed/32967382 http://dx.doi.org/10.3390/diagnostics10090730 |
_version_ | 1783593936448651264 |
---|---|
author | Martin, Benedikt Mayr, Patrick Ihringer, Regina Schäfer, Eva-Maria Jakubowicz, Elżbieta Anthuber, Matthias Schenkirsch, Gerhard Schaller, Tina Märkl, Bruno |
author_facet | Martin, Benedikt Mayr, Patrick Ihringer, Regina Schäfer, Eva-Maria Jakubowicz, Elżbieta Anthuber, Matthias Schenkirsch, Gerhard Schaller, Tina Märkl, Bruno |
author_sort | Martin, Benedikt |
collection | PubMed |
description | The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cytokeratin immunohistochemistry can improve the interobserver variability and prognostic significance. Six investigators with different levels of experience reassessed 229 cases of colon carcinoma (pT3/4, N+/−, M0) with a supporting cytokeratin immunohistochemistry. The results were compared to previous assessments, which have been performed only on H & E. Bd3 was significantly associated with the occurrence of distant metastases according to the assessments of three out of six investigators (p < 0.05). Only one single investigator reached significant results concerning the cancer specific survival (p = 0.01). The pairwise kappa values range between a poor and moderate level of agreement (range 0.17–0.45; median 0.21). In conclusion, the results show no superiority of the use of an additional cytokeratin immunohistochemistry compared to the conventional analysis on sole H & E slides. Therefore, the general supporting use of a cytokeratin immunohistochemical staining seems to be inadvisable in colon cancer in consideration of necessary resources and costs. |
format | Online Article Text |
id | pubmed-7555133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75551332020-10-14 Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? Martin, Benedikt Mayr, Patrick Ihringer, Regina Schäfer, Eva-Maria Jakubowicz, Elżbieta Anthuber, Matthias Schenkirsch, Gerhard Schaller, Tina Märkl, Bruno Diagnostics (Basel) Brief Report The prognostic significance of tumor budding in colon cancer is unequivocally documented, and the recommendations of the International Tumor Budding Consensus Conference (ITBCC) are currently the accepted basis for its assessment. Up to now, it is unknown whether the general use of a supporting cytokeratin immunohistochemistry can improve the interobserver variability and prognostic significance. Six investigators with different levels of experience reassessed 229 cases of colon carcinoma (pT3/4, N+/−, M0) with a supporting cytokeratin immunohistochemistry. The results were compared to previous assessments, which have been performed only on H & E. Bd3 was significantly associated with the occurrence of distant metastases according to the assessments of three out of six investigators (p < 0.05). Only one single investigator reached significant results concerning the cancer specific survival (p = 0.01). The pairwise kappa values range between a poor and moderate level of agreement (range 0.17–0.45; median 0.21). In conclusion, the results show no superiority of the use of an additional cytokeratin immunohistochemistry compared to the conventional analysis on sole H & E slides. Therefore, the general supporting use of a cytokeratin immunohistochemical staining seems to be inadvisable in colon cancer in consideration of necessary resources and costs. MDPI 2020-09-21 /pmc/articles/PMC7555133/ /pubmed/32967382 http://dx.doi.org/10.3390/diagnostics10090730 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Martin, Benedikt Mayr, Patrick Ihringer, Regina Schäfer, Eva-Maria Jakubowicz, Elżbieta Anthuber, Matthias Schenkirsch, Gerhard Schaller, Tina Märkl, Bruno Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title | Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title_full | Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title_fullStr | Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title_full_unstemmed | Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title_short | Interobserver Variability in the Assessment of Tumor Budding in pT 3/4 Colon Cancer: Improvement by Supporting Immunohistochemistry? |
title_sort | interobserver variability in the assessment of tumor budding in pt 3/4 colon cancer: improvement by supporting immunohistochemistry? |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555133/ https://www.ncbi.nlm.nih.gov/pubmed/32967382 http://dx.doi.org/10.3390/diagnostics10090730 |
work_keys_str_mv | AT martinbenedikt interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT mayrpatrick interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT ihringerregina interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT schaferevamaria interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT jakubowiczelzbieta interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT anthubermatthias interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT schenkirschgerhard interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT schallertina interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry AT marklbruno interobservervariabilityintheassessmentoftumorbuddinginpt34coloncancerimprovementbysupportingimmunohistochemistry |